Bielsky Alan R, Fuhr Peter G, Parsons Julie A, Yaster Myron
Departments of Anesthesiology and Neurology, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado.
Paediatr Anaesth. 2018 Dec;28(12):1105-1108. doi: 10.1111/pan.13500. Epub 2018 Oct 4.
Spinal muscular atrophy is characterized by loss of motor neurons in the anterior horn of the spinal cord with resultant proximal muscle weakness. Intrathecal nusinersen has revolutionized the treatment of spinal muscular atrophy. We reviewed the perioperative care of 61 anesthetics performed on eight patients with spinal muscular atrophy type 2 who received nusinersen over 30 months in conjunction with nusinersen's phase 3 clinical trials.
Anesthesia was induced in all patients with sevoflurane, nitrous oxide, and oxygen (30%) via facemask. A peripheral intravenous line was placed after the loss of consciousness in all but three procedures. General anesthesia was maintained in 58 anesthetics with a propofol infusion at 250-300 μg/kg/min, while the remainder was maintained with inhalational anesthetics. The airway was managed via facemask or nasal cannula in all but two procedures, in whom a laryngeal mask airway was placed. We analyzed patient demographics, duration of anesthesia and of postanesthesia care unit stay, discharge destination, preprocedure oxygen saturation (SaO ), postanesthesia care unit discharge oxygen saturation, and occurrence of unanticipated admission or postdischarge hospitalization.
Eight American Society of Anesthesiologists physical status three patients (3 male: 5 female) with a median age of 4.1 (2.1-7.8) years and median weight of 13.2 (10-24.7) kg, underwent 61 anesthetics for nusinersen administration or sham procedure. There were no intraoperative anesthetic complications of unanticipated cardiovascular instability, major neurologic events, respiratory failure, or death. Anesthesiologists performed 83% of the procedures.
Nusinersen has revolutionized the care of patients with spinal muscular atrophy type 2 and anesthesiologists will be involved in its administration. We found that routine anesthetic care was safe and effective.
脊髓性肌萎缩症的特征是脊髓前角运动神经元丧失,导致近端肌无力。鞘内注射诺西那生钠彻底改变了脊髓性肌萎缩症的治疗方法。我们回顾了8例2型脊髓性肌萎缩症患者在30个月内接受诺西那生钠治疗期间进行的61次麻醉的围手术期护理情况,这些护理是与诺西那生钠的3期临床试验同时进行的。
所有患者均通过面罩吸入七氟烷、氧化亚氮和氧气(30%)诱导麻醉。除3例手术外,其余手术均在患者意识丧失后建立外周静脉通路。58例麻醉采用丙泊酚以250 - 300μg/kg/min的速度输注维持全身麻醉,其余则采用吸入麻醉维持。除2例手术放置喉罩气道外,其余手术均通过面罩或鼻导管管理气道。我们分析了患者的人口统计学资料、麻醉持续时间、麻醉后监护病房停留时间、出院目的地、术前血氧饱和度(SaO)、麻醉后监护病房出院时的血氧饱和度以及意外入院或出院后住院的发生情况。
8例美国麻醉医师协会身体状况分级为3级的患者(3例男性,5例女性),中位年龄为4.1(2.1 - 7.8)岁,中位体重为13.2(10 - 24.7)kg,接受了61次用于诺西那生钠给药或假手术的麻醉。术中未发生意外的心血管不稳定、重大神经事件、呼吸衰竭或死亡等麻醉并发症。83%的手术由麻醉医师实施。
诺西那生钠彻底改变了2型脊髓性肌萎缩症患者的护理方式,麻醉医师将参与其给药过程。我们发现常规麻醉护理是安全有效的。